

Group Continuous Disclosure Policy



PEXA Group Limited (Company)

ACN 629 193 764

v 4.0

December 2025

Document control

Title: Continuous Disclosure Policy

Approved by the Board on 19 December 2025

Contact for inquiries and proposed changes:

Company Secretary

SCOPE

This policy sets out how PEXA Group Limited (PEXA Group) satisfies its obligation as a listed company to immediately disclose price sensitive information to the Australian Securities Exchange (ASX). It acknowledges the importance of PEXA Group's market announcements being: timely, accurate, balanced and expressed in a clear and objective manner that allows investors to assess the impact of the information when making investment decisions.

If you do not understand any part of this policy, or how it applies to you, you should raise the matter with your manager or one of the contacts listed at the end of this document.

This Continuous Disclosure Policy applies to all executive and non-executive directors, officers, employees, contractors and consultants of the Company and its subsidiaries (Personnel) wherever located (ie Australia, UK or any other location).

PURPOSE

This policy identifies the persons responsible for making decisions about what information will be disclosed to the market via ASX.

Guidelines are available to assist in understanding what information may be price sensitive, and therefore required to be disclosed to the market via ASX. However, the determination of whether information is price sensitive and whether an exception to the requirement to disclose applies is a matter for those with authority under this policy.

DISCLOSURE REQUIREMENTS

PEXA Group must immediately notify the ASX of any information concerning PEXA Group that a reasonable person would expect to have a material effect on the price or value of PEXA Group securities ("price sensitive information"). Information is likely to have a "material effect" if it is likely that the information would influence investors in deciding whether to buy, hold or sell PEXA Group securities.

However there is an exception to this disclosure requirement.

Disclosure is not required whilst all three of the following conditions are met:

1. One or more of the following situations apply:
 - it would be a breach of a law to disclose the information;
 - the information concerns an incomplete proposal or negotiation;
 - the information comprises matters of supposition or is insufficiently definite to warrant disclosure;
 - the information is generated for PEXA Group's internal management purposes; or
 - the information is a trade secret; and
2. The information is confidential (and ASX has not formed the view that the information has ceased to be confidential); and
3. A reasonable person would not expect the information to be disclosed.

To assist in managing these requirements PEXA Group has established a Continuous Disclosure Committee (CDC) consisting of the:

- Group CEO & MD;
- Group Chief Financial Officer;
- Company Secretary; and
- Head of Investor Relations.

Each member of the CDC is a “Disclosure Officer” under this policy.

REPORTING INFORMATION TO DISCLOSURE OFFICERS

If any Personnel becomes aware of information that they consider is potentially price sensitive in respect of PEXA securities, they must immediately advise a Disclosure Officer or another member of the Executive Leadership Team (who must in turn notify a CDC member).

Potentially price sensitive information must be disclosed to a Disclosure Officer.

Personnel must not disclose potentially price sensitive information to a third party (e.g. a supplier, contractor, customer) unless it has been disclosed to ASX or they have specific approval from a Disclosure Officer.

In accordance with the ASX Listing Rules the Disclosure Officer will as soon as possible discuss any potentially price sensitive matter advised to them with other members of the CDC to determine if the information is possibly price sensitive. If it is possibly price sensitive the CDC will be convened as soon as possible to consider the matter. External advisors, and other management, will be invited to join CDC meetings as determined by CDC members, based on all relevant circumstances.

If the CDC clearly determines that there is no new materially price sensitive information and/or no disclosure is required, this will be noted and no further action taken. If the CDC determines that there is new materially price sensitive information, and/or market disclosure is required or, the position is not clear or is uncertain, the CDC will consult with the PEXA Group Board Chair, and if necessary the Board, and take appropriate actions to ensure compliance with the ASX Listing Rules.

The CDC will oversee the preparation of, and endorse, any announcement to the ASX.

As soon as practicable following a meeting of the CDC, the Board will be provided with a summary of the meeting.

ROLES, RESPONSIBILITIES AND APPROVAL REQUIREMENTS

The types of ASX releases issued by PEXA Group and the approval and consultation requirements for ASX releases are set out in the table below.

| | Description | Approval | Consultation |
|---------------|--|---|---|
| Type A | Releases dealing with matters of strategic significance to PEXA Group, or to PEXA Group's reputation, major company transforming events or transactions and results or other earnings or outlook related announcements (including earnings upgrades and downgrades). | <ul style="list-style-type: none"> • PGL Board • (or if unavailable in required time frame PGL Chair and if unavailable Group CEO & MD) | <ul style="list-style-type: none"> • Group CEO & MD • Group CFO • Company Secretary • GM Investor Relations |
| Type B | Other releases relating to matters reserved to the Board under the Delegation of Authority Policy (e.g. major contracts and transactions not covered by Type A). | <ul style="list-style-type: none"> • Group CEO&MD • (or Board if required by PGL Chairman) | <ul style="list-style-type: none"> • PGL Board • Group CFO • Company Secretary • GM Investor Relations |
| Type C | Administrative releases required by law or regulation (e.g. changes to issued capital, changes in Director shareholdings, etc). | <ul style="list-style-type: none"> • Company Secretary | <ul style="list-style-type: none"> • N/A |
| Type D | <ol style="list-style-type: none"> 1. "Holding statements" about price sensitive information in advance of a more detailed Type A or Type B Release being made (e.g. a release confirming the occurrence of an event and foreshadowing that more detailed information will be provided when available); or 2. a request for a trading halt, incircumstances where the GROUP CEO & MD reasonably believes that a trading halt or holding statement is necessary without delay in order to comply with PEXA Group's Continuous Disclosure obligations. | <ul style="list-style-type: none"> • PGL Board • (or if unavailable in required time frame PGL Chair and if unavailable Group CEO & MD) | <ul style="list-style-type: none"> • Group CEO & MD • Group CFO • Company Secretary • GM Investor Relations |
| Type E | Other releases, not included in the above categories | <ul style="list-style-type: none"> • Group CEO&MD • (or Board if required by Chairman) | <ul style="list-style-type: none"> • PGL Chair • Group CFO • Company Secretary • GM Investor Relations |

Directors will be provided with a copy of all ASX Releases, (other than type C administrative announcements), prior to them being released to the ASX. If this is not practical in the required time frame, due to extreme circumstances, they will be provided to Directors as soon as possible.

In addition to the consultation requirements in the above table, depending on the subject matter of the disclosure, review and/or approval of a Board Committee may be required (see below).

Under the Listing Rules, PEXA Group may be required to make an announcement to ASX "immediately" (that is, promptly and without delay).

The exact time period will depend upon the circumstances. Where a person required to approve a release is not available in the time required to approve, the following alternates may approve:

| Approver | Alternate Arrangements |
|-----------------------|---|
| Group CEO & MD | Duly appointed delegate, or failing them, Group CFO |
| PGL Chair | Chair of the Audit and Risk Committee, or failing them Group CEO and MD |
| PGL Board | Available PGL Directors |
| Group CFO | Duly appointed delegate, or failing them, GM Investor Relations |
| GM Investor Relations | Duly appointed delegate, or failing them, Group CFO |
| Company Secretary | General Counsel Australia |

Once the relevant approval and consultation requirements have been satisfied, the Company Secretary or their delegate is authorised to lodge the relevant documents with the ASX.

ROLE OF BOARD COMMITTEES

In the case of announcements to ASX that relate to periodic disclosure (i.e. annual and half year results), consultation or approval of any relevant Board Committee must be obtained where the Charter of a Committee requires it to review, approve and/or recommend to the Board matters which constitute or are included in an ASX release (e.g. Audit and Risk Committee to approve Financial Statements, Remuneration. Nomination and People Committee to approve Remuneration Report).

PREPARING MARKET ANNOUNCEMENTS

Where it has been determined (in accordance with this policy) that information will be publicly disclosed, one or more CDC members will oversee preparation of that announcement. The CDC is responsible for satisfying itself that the content of any announcement is accurate and not misleading and supported by appropriate verification.

Where any information is reported under this Policy and the CDC determines that the circumstances are developing but the information is not presently disclosable, the CDC will oversee the preparation of a “draft” ASX announcement to facilitate immediate disclosure of the information if it later becomes disclosable.

The CDC will endorse all ASX announcements, other than announcements of purely an administrative nature (which will be approved by the Company Secretary), or media releases that are not market sensitive, or announcements approved by the Board or CEO & MD, prior to release. The CDC’s endorsement will be recorded by the Company Secretary.

The PEXA Group Board, CEO & MD and Company Secretary, and their alternates (if any), are the only persons authorised to direct the release of ASX announcements.

MANAGING MARKET SPECULATION AND RUMOURS

Market speculation and rumour, whether substantiated or not, have potential to impact PEXA Group. Speculation may also result in ASX formally requesting disclosure by PEXA Group on the matter. Speculation may also contain factual errors that could materially affect the Company.

PEXA Group's policy on responding to market speculation and rumours is that "the Company does not respond to market speculation or rumours". This policy must be observed by employees at all times. The Group CEO & MD will decide if a response is required or a comment is to be made, based on the specific circumstances at the time.

The Board will be kept advised, and updated, as to Market speculation and rumors regarding the Company and matters impacting its operations.

Guidance is available to employees on responding to requests from third parties (such as media, investors and government) and on required internal notifications.

PEXA Group's policy of no comment for employees extends to usage of social media.

COMMUNICATION OF DISCLOSABLE INFORMATION

All market sensitive disclosure will first be made available on the ASX Market Announcements Platform (MAP).

PEXA Group must not release information publicly that is required to be disclosed through ASX until it has received formal confirmation of its release by ASX. The Company Secretary (or their delegate) will confirm that receipt in writing.

Once acknowledgement is received that the announcement has been released, PEXA Group may communicate the information to other stakeholders, such as media, analysts, shareholders and employees, via appropriate channels and technologies including on its website, social media platforms and via email.

All information disclosed to ASX will be promptly placed on PEXA Group's website.

If not already done so, the Company Secretary will provide the PEXA Group Board with a copy of all, non administrative, market announcements promptly after release on the MAP.

AUTHORISED SPOKESPERSONS

The Chairman and the Group CEO & MD are authorised spokespersons for the Company.

When an ASX Release is approved under this policy, any additional persons authorised to act as spokespersons will be set out in the Release or otherwise authorised by the Group CEO & MD.

In accordance with PEXA's "Group-Public Comment" Policy, only authorised PEXA Group staff may communicate with third parties. Personnel must not speak with the media, analysts, investors about any matters connected to PEXA Group (including any subsidiary or joint venture in which PEXA Group is involved) unless authorised to do so. Speaking with third parties can create high risks in relation to PEXA Group's continuous disclosure obligations. Personnel should not disclose or discuss market sensitive information with other PEXA Personnel.

MEETINGS WITH INVESTORS AND ANALYSTS

PEXA Group will not disclose market sensitive information in any meeting with an investor or analyst before formally disclosing it to the ASX.

PEXA Group considers one-on-one discussions and meetings with investors and analysts as an important part of proactive investor relations. However, PEXA Group will only discuss previously disclosed information, or information that is not market sensitive, in such meetings.

The CDC must be advised immediately after those meetings in cases where information inadvertently discussed may need to be disclosed.

Before PEXA Group gives a new and substantive presentation to investors or analysts, it will release a copy of that presentation to the ASX.

The Group CFO and the GM Investor Relations will ensure that a file note is made of all meetings and briefings with investors or analysts.

Any PEXA Group employee at a meeting or briefing, who considers that market sensitive information has been raised, that previously has not been disclosed, must immediately refer that matter to a Disclosure Officer.

NO EMBARGO OF INFORMATION

Information must not be provided to third parties (e.g. analysts or journalists), under an embargo arrangement in relation to any matter that is potentially the subject of this policy. This is because price sensitive information must be given to the ASX before it becomes known to anyone outside PEXA Group.

ANALYST REPORTS AND FORECASTS

The Group CFO and Head of Investor Relations will monitor analyst reports and forecasts to determine whether the forecasts diverge materially from PEXA Group's relevant internal forecasts and (if applicable) any guidance published by PEXA Group. If so, the CDC will consider whether PEXA Group is required to make further disclosure.

TRADING HALTS

The Group CEO & MD has approval to request a trading halt (see Type D Releases above).

BREACHES OF POLICY

Strict compliance with this policy is a condition of employment. Breaches of this policy will be subject to disciplinary action, which may include termination of employment.

REVIEW OF POLICY

This policy will be reviewed annually or as otherwise deemed appropriate to ensure that it is

operating effectively and to determine whether any changes are required. Any amendments to the policy must be approved by the Board, except for minor administrative updates and amendments, which may be approved by the Disclosure Committee.